Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress

DeeDee K Smart1, Karen L Ortiz, David Mattson

  • 1Molecular Radiation Oncology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Cancer Research
|September 18, 2004
PubMed

Insights

Thioredoxin reductase 1 (TR) inhibition enhances cancer cell sensitivity to oxidative stress and anticancer agents. Targeting TR can increase tumor cell death when combined with treatments like hydrogen peroxide and ionizing radiation.

Area of Science:

  • Cellular Biology
  • Biochemistry
  • Oncology

Background:

  • Redox-sensitive signaling pathways regulate crucial cellular processes like proliferation and survival.
  • These pathways are potential targets for developing novel anticancer agents.
  • Thioredoxin reductase 1 (TR) is a key enzyme in redox regulation and a candidate molecular target.

Purpose of the Study:

  • To investigate thioredoxin reductase 1 (TR) as a molecular target for enhancing anticancer therapies.
  • To determine if inhibiting TR increases sensitivity to oxidative stress-inducing agents.
  • To evaluate the effects of TR inhibition on cell signaling, cell cycle, and cytotoxicity.

Main Methods:

  • Utilized HeLa cells overexpressing wild-type (pCXN2-myc-TR-wt) or mutant (pCXN2-myc-mTR) TR genes.
  • Treated cells with the TR inhibitor 1-methyl-1-propyl-2-imidazolyl disulfide (IV-2).
  • Exposed cells to oxidative stressors hydrogen peroxide (H2O2) and ionizing radiation (IR), analyzing signal transduction, cell cycle, and cytotoxicity.

Main Results:

  • TR inhibition (via mutant TR or IV-2) blocked NF-kappaB and AP-1 activation in response to oxidative stress.
  • TR inhibition caused G1 phase cell cycle arrest and inhibited proliferation.
  • Cells with inhibited TR showed significantly increased sensitivity to H2O2 and IR-induced cytotoxicity.

Conclusions:

  • Thioredoxin reductase 1 (TR) is a viable molecular target for cancer therapy.
  • Inhibiting TR potentiates the cytotoxic effects of oxidative stress-inducing agents like IR.
  • Targeting TR offers a strategy to enhance the efficacy of existing anticancer treatments.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Redox Reactions01:27

Redox Reactions

Redox reactions are vital biochemical processes that underpin energy metabolism in cells. These reactions involve the transfer of electrons between molecules, occurring in tandem as oxidation and reduction. Oxidation refers to the loss of electrons, while reduction denotes their gain. This coupling ensures the seamless flow of electrons through metabolic pathways. For example, in bacterial metabolism, glucose undergoes oxidation to carbon dioxide, while oxygen is simultaneously reduced to...